Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Cd73 Expression

Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

Annals of Oncology ◽

10.1093/annonc/mdx138.005 ◽

2017 ◽

Vol 28 ◽

pp. i11 ◽

Cited By ~ 1

Author(s):

L. Buisseret ◽

S. Pommey ◽

B. Allard ◽

S. Garaud ◽

L. Ameye ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Clinical Significance ◽

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Cd73 Expression

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

Annals of Oncology ◽

10.1093/annonc/mdx730 ◽

2018 ◽

Vol 29 (4) ◽

pp. 1056-1062 ◽

Cited By ~ 50

Author(s):

L. Buisseret ◽

S. Pommey ◽

B. Allard ◽

S. Garaud ◽

M. Bergeron ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Clinical Significance ◽

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Multiplex Analysis

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

Annals of Oncology ◽

10.1093/annonc/mdz097.014 ◽

2019 ◽

Vol 30 ◽

pp. iii38

Author(s):

S. Loibl ◽

C. Jackisch ◽

P. Rastogi ◽

S. Seiler ◽

P.C. Lucas ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

10.1158/1538-7445.sabcs18-ot3-05-01 ◽

2019 ◽

Author(s):

CE Geyer ◽

S Loibl ◽

P Rastogi ◽

S Seiler ◽

JP Costantino ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

10.1158/1538-7445.sabcs19-ot2-04-08 ◽

2020 ◽

Author(s):

Charles E Geyer ◽

Sibylle Loibl ◽

Priya Rastogi ◽

Sabine Seiler ◽

Joseph P Costantino ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps603 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS603-TPS603 ◽

Cited By ~ 2

Author(s):

Charles E. Geyer ◽

Sibylle Loibl ◽

Priya Rastogi ◽

Sabine Seiler ◽

Joseph P. Costantino ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3863-3 ◽

2016 ◽

Vol 158 (2) ◽

pp. 323-331 ◽

Cited By ~ 58

Author(s):

Giancarlo Pruneri ◽

Kathryn P. Gray ◽

Andrea Vingiani ◽

Giuseppe Viale ◽

Giuseppe Curigliano ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Prognostic Marker ◽

Triple Negative ◽

Tumor Infiltrating Lymphocytes ◽

Phase Iii ◽

Infiltrating Lymphocytes

100P Phase III of study of docetaxel and carboplatin with or without doxorubicin hydrochloride and cyclophosphamide in treating women with triple negative breast cancer

Annals of Oncology ◽

10.1016/s0923-7534(21)00259-3 ◽

2016 ◽

Vol 27 ◽

pp. ix30

Author(s):

S. Najafi ◽

M. Payandeh ◽

M. Sadeghi ◽

F. Zahra Shojaiyan ◽

F. Abbasvandi ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Doxorubicin Hydrochloride

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06307-3 ◽

2021 ◽

Author(s):

Foluso O. Ademuyiwa ◽

Ina Chen ◽

Jingqin Luo ◽

Mothaffar F. Rimawi ◽

Ian S. Hagemann ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Pathological Response

248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.369 ◽

2020 ◽

Vol 31 ◽

pp. S339

Author(s):

S. Loibl ◽

P. Rastogi ◽

S. Seiler ◽

C. Jackisch ◽

P.C. Lucas ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial